Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 6/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KIT | P10721 | 3/20 | 0.46 |
| ▸ | JAK3 | P52333 | 3/20 | 0.45 |
| ▸ | JAK1 | P23458 | 2/20 | 0.45 |
| ▸ | TYK2 | P29597 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | IGF1R | P08069 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4047768 | 0.88 | FLT3 (0.64) | FLT3LMNAIMPDH2GLASMN1; SMN2 | |
| SCHEMBL12779064 | 0.85 | FLT3 (0.55) | FLT3LMNAIMPDH2GLASMN1; SMN2 | |
| SCHEMBL4038724 | 0.77 | FLT3 (0.50) | FLT3LMNAGLASMN1; SMN2KIT | |
| SCHEMBL6643904 | 0.77 | FLT3 (0.63) | FLT3KITJAK3JAK1TYK2 | |
| SCHEMBL30299331 | 0.77 | CYP11B2 (0.42) | SMN1; SMN2ALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL4039312 | 0.76 | FLT3 (0.62) | FLT3LMNAIMPDH2GLASMN1; SMN2 | |
| SCHEMBL14275831 | 0.76 | FLT3 (0.49) | FLT3LMNAGLASMN1; SMN2KIT | |
| SCHEMBL4038418 | 0.76 | FLT3 (0.65) | FLT3LMNAIMPDH2SMN1; SMN2KIT | |
| SCHEMBL4037878 | 0.75 | FLT3 (0.73) | FLT3KITJAK3JAK2 | |
| SCHEMBL4039213 | 0.75 | FLT3 (0.64) | FLT3LMNAIMPDH2SMN1; SMN2KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312390-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA | ALCON, INC. (CH) | 2009-12-17 | — | — | US | claimed |
| EP-1430120-A4 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA | ALCON INC (CH) | 2007-06-20 | — | — | EP | claimed |
| US-20040186159-A1 | Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma | NOVARTIS AG (CH) | 2004-09-23 | — | — | US | claimed |
| EP-1430120-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA | Alcon, Inc. (CH) | 2004-06-23 | — | — | EP | claimed |
| WO-2003027275-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA | ALCON, INC. (CH) | 2003-04-03 | — | — | WO | claimed |
| EP-2281560-A1 | Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucomatous optic neuropathy | Alcon, Inc. (CH) | 2011-02-09 | — | — | EP | disclosed |
| US-20090312390-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA | ALCON, INC. (CH) | 2009-12-17 | — | — | US | disclosed |
| US-7598288-B2 | Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma | ALCON, INC. (CH) | 2009-10-06 | — | — | US | disclosed |
| US-20040186159-A1 | Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma | NOVARTIS AG (CH) | 2004-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186159-A1 | Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma | GSK3B, GSK3A, GSKIP | FLT3 4673/4885LMNA 1248/4885IMPDH2 2372/4885 |
| US-20090312390-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA | GSK3B, GSK3A, GSKIP | FLT3 4673/4885LMNA 1248/4885IMPDH2 2372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.